WebJan 12, 2024 · "We are pleased by the top-line results from our LiFT study, which we believe demonstrate the potential for oral LPCN 1144's to be used in treating NASH," said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine Inc. "Additionally, NASH patients are likely to have compromised androgen signaling with associated sarcopenia, skeletal ... WebApr 3, 2024 · About Lipocine Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to …
Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 …
WebMar 25, 2024 · Lipocine Inc. (NASDAQ:LPCN – Get Rating) CEO Mahesh V. Patel acquired 150,000 shares of Lipocine stock in a transaction on Friday, March 24th. The shares were bought at an average price of $0.32 per share, for a total transaction of $48,000.00. Following the purchase, the chief executive officer now owns 1,678,090 … WebDec 19, 2024 · "We are excited to complete enrollment which leads to topline results mid-2024 for a serious end-stage condition with high unmet medical need," said Dr. Mahesh Patel, President and CEO of... convert rpm to in/sec
Lipocine Announces Favorable Regulatory Pathway on Oral …
WebApr 3, 2024 · The study is expected to enroll a total of 12 participants and is being conducted at a single center in the US. Results are expected in the first half of 2024. "We are excited about our development progress for LPCN 1154," said Dr. Mahesh Patel, President and CEO of Lipocine Inc. http://corp.hiltonmanage.com/corporate/wp-content/uploads/2024/08/2024-US-Hampton-FDD-.pdf WebApr 14, 2024 · In other Lipocine news, CEO Mahesh V. Patel bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, March 24th. The stock was acquired … false creek vancouver condos